When was Beactica founded?

Beactica was founded in 2006 and raised its 1st funding round 3 years after it was founded.

Where is Beactica located?

Beactica is headquartered in Uppsala, Sweden.

How many employees does Beactica have?

As of May 31, 2026, the latest employee count at Beactica is 16.

Is Beactica a funded company?

Beactica is a funded company, having raised an undisclosed amount across 12 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2009.

When was the latest funding round of Beactica?

Beactica's latest funding was a $***** Grant (prize money) round on Feb 17, 2026, with participation from 1 investor. Its primary sector is Oncology. In Sweden, the Oncology sector has seen $12.7M in funding in 2026 to date.

Where does Beactica rank among its competitors?

Beactica ranks 413th amongst 3261 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Beactica?

Beactica's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Beactica - 2026 Company Profile, Team, Funding & Competitors

Beactica is a series A company based in Uppsala (Sweden), founded in 2006 by Per Källblad. It operates as a Develops small molecule drugs for oncology. Beactica has raised an undisclosed amount in funding from Unionen and Almi Invest. The company has 3261 active competitors, including 1122 funded and 772 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.

Website: www.beactica.com/
Social

Key Metrics

Founded Year

2006

Location

Uppsala, Sweden

Stage

Series A

Latest Funding Round

Grant (prize money), Feb 17, 2026, $*****

Investors

Unionen & 8 more

Ranked

413^th among 3261 active competitors

Employee Count

16 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2977 more

View Beactica's full profile

Beactica has raised funding over 12 rounds. Its first funding round was on 2009. Its latest funding round was a Grant (prize money) round on Feb 17, 2026 for $*****. 1 investor participated in its latest round. Beactica has 9 institutional investors.

Here is the list of recent funding rounds of Beactica:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 17, 2026	6410064	Grant (prize money)	6258453	8171893	7757742	8325000
Dec 01, 2019	2583733	Grant (prize money)	6372142	9740814	3015999	Europa
Jun 04, 2019	9679295	Series A	5789076	2201983	Unionen & 1 more	M2 Capital Management

Access funding benchmarks and valuations. Sign up today!

View details of Beactica's funding rounds and investors

The founders of Beactica is Per Källblad.

Here are the details of Beactica's key team members:

Per Källblad: Co-Founder & CEO of Beactica.

View details of Beactica's Founder profiles and Board Members

Beactica's employee count trend

Beactica has 16 employees as of May 26. Here is Beactica's employee count trend over the years:

Uncover Beactica's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beactica include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Beactica, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Eight Roads Ventures & 23 others	71/100
413th	Beactica 2006, Uppsala (Sweden), Series A	Develops small molecule drugs for oncology	-	Vinnova, Unionen & 7 others	55/100